These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16048459)

  • 21. Neuroleptic equivalent dose differences and behavioral and psychological symptoms of dementia.
    Tremolizzo L; Tironi M; Ferrarese C; Appollonio I
    Dement Geriatr Cogn Disord; 2013; 35(1-2):118-20. PubMed ID: 23392226
    [No Abstract]   [Full Text] [Related]  

  • 22. [Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients].
    Shimabukuro J; Awata S; Matsuoka H
    Seishin Shinkeigaku Zasshi; 2008; 110(7):529-35. PubMed ID: 18833901
    [No Abstract]   [Full Text] [Related]  

  • 23. Phenomenological distinctions needed in DSM-V: delirium, subsyndromal delirium, and dementias.
    Meagher D; Trzepacz PT
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):468-70. PubMed ID: 18070853
    [No Abstract]   [Full Text] [Related]  

  • 24. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal.
    Tanii H; Fujita K; Okazaki Y
    Am J Psychiatry; 2006 Mar; 163(3):547-8. PubMed ID: 16513884
    [No Abstract]   [Full Text] [Related]  

  • 25. Anticholinergic drugs and physical function among frail elderly population.
    Landi F; Russo A; Liperoti R; Cesari M; Barillaro C; Pahor M; Bernabei R; Onder G
    Clin Pharmacol Ther; 2007 Feb; 81(2):235-41. PubMed ID: 17192773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of anticholinergic use among older home health patients.
    McNeely SS; Bhattacharya R; Aparasu RR
    J Clin Nurs; 2013 Jan; 22(1-2):285-8. PubMed ID: 23216557
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug-induced confusional states: the usual suspects?
    Hufschmidt A; Shabarin V; Zimmer T
    Acta Neurol Scand; 2009 Dec; 120(6):436-8. PubMed ID: 19804475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dementia patients caregivers quality of life: the PIXEL study.
    Thomas P; Lalloué F; Preux PM; Hazif-Thomas C; Pariel S; Inscale R; Belmin J; Clément JP
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):50-6. PubMed ID: 16323256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychiatric outcome for clinical trials.
    Robert P; Verhey FR; Aalten P; Cortes F; Byrne EJ
    J Nutr Health Aging; 2007; 11(4):345-7. PubMed ID: 17653496
    [No Abstract]   [Full Text] [Related]  

  • 30. Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Whitehouse PJ; Orgogozo JM; Becker RE; Gauthier S; Pontecorvo M; Erzigkeit H; Rogers S; Mohs RC; Bodick N; Bruno G; Dal-Bianco P
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():56-60. PubMed ID: 9305519
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurochemical approaches to the treatment of senile dementia.
    Growdon JH; Corkin S
    Proc Annu Meet Am Psychopathol Assoc; 1980; 69():281-96. PubMed ID: 7413654
    [No Abstract]   [Full Text] [Related]  

  • 32. Electroconvulsive monotherapy in the treatment of acute confusion psychosis. A case report.
    Neuhaus AH; Katchanov J; Opgen-Rhein C; Neu P; Jockers-Scherübl MC
    Pharmacopsychiatry; 2005 Nov; 38(6):330-2. PubMed ID: 16342009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing dementia.
    Ticehurst S
    Aust N Z J Psychiatry; 1988 Mar; 22(1):3. PubMed ID: 2897193
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study.
    Griebling TL
    J Urol; 2014 Aug; 192(2):490. PubMed ID: 25035017
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia.
    Chew ML; Mulsant BH; Pollock BG
    Am J Geriatr Psychiatry; 2005 Jun; 13(6):535-8. PubMed ID: 15956274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
    Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication-induced dystonias in nine patients with dementia.
    Magnuson TM; Roccaforte WH; Wengel SP; Burke WJ
    J Neuropsychiatry Clin Neurosci; 2000; 12(2):219-25. PubMed ID: 11001600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
    Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.
    Lim HK; Pae CU; Lee C; Lee CU
    Neuropsychobiology; 2006; 54(4):247-51. PubMed ID: 17356308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of dementia: anything new?
    Machado JC; Caramelli P
    Curr Opin Psychiatry; 2006 Nov; 19(6):575-80. PubMed ID: 17012934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.